CC-93538
Phase 3Small molecule
Bristol-Myers SquibbCC-93538 is one of 14 small molecule programs targeting Eosinophilic Esophagitis. It is currently in Phase 3.
1
Indications
6
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Eosinophilic Esophagitis
#DrugCompanyPhaseTrials
1Pulmicort
SSalix
Approved
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Approved
Flovent
PParatek Pharmaceuticals Inc
Approved
Prevacid
TakedaApproved
Flovent
PParatek Pharmaceuticals Inc
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Tezspire
AstraZenecaPhase 3
CC-93538
Bristol-Myers SquibbPhase 3
Omeprazole BID
UUniversity of Colorado, Denver
Phase 3
Solrikitug
UUniquity One (UNI)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Eosinophilic Esophagitis2 trials
Atopic Dermatitis1 trial
Concentration1 trial
Gastroenteritis1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CC-93538. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company